If you want to buy Dutasteride Online
Click here to Compare Price of
Dutasteride
|
FDA approval for
Dutasteride – Avodart |
Getting any medication product cleared or approved by the U.S.
FDA is the matter of great concern for any pharmaceutical enterprise
operating across the world. The US FDA has granted the formal
approval to the supplemental latest drug application for the Brand
Avodart made from the Generic Dutasteride formulated by
GlaxoSmithKline-GSK for the treatment of symptomatic benign
prostatic hyperplasia-BPH in male patients having the expanded
prostate gland for improving the urinary symptoms, diminish the risk
of severe or acute urinary retention called AUR as well as minimize
the risk of need for BPH connected surgical operations.
Based on the clinical trials, the pill form drug Avodart is the
second generation 5-alpha reductase inhibitor which is considered to
be the first and perhaps the only drug to slow down both the type 1
and type 2 enzymes that are primarily responsible for the adaptation
of testosterone to Dihydrotestosterone-DHT which is believed to be
the basic cause of prostate growth. The dual retention of Avodart
diminishes the levels of DHT by 90 percent within two weeks and by
93 percent within the span of 2 years.
Avodart decreases the size of expanded prostate gland by diminishing
the DHT levels. Such diminutions in the prostate volume had been
noticed as early as one month with continued decrease through
recommended treatments in the clinical studies. Constricting the
expanded prostate relieves urinary related obstruction and enhances
the urinary flow. Avodart is also believed to improve urinary
symptoms and diminishes the risk of AUR which means the abrupt total
inability of urinating as well as BPH connected surgical operations
and a couple of potential prolonged serious effects of BPH.
|
|
